(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Portfolio Pulse from Benzinga Insights
Biomarin Pharmaceutical's short interest has decreased by 8.08%, with 6.88 million shares sold short, representing 3.64% of its float. This is lower than the peer group average of 6.33%. The decrease in short interest may indicate a more bullish sentiment towards the stock.

August 21, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomarin Pharmaceutical's short interest has decreased by 8.08%, now at 3.64% of its float, which is below the peer average of 6.33%. This reduction may suggest a shift towards a more bullish market sentiment.
The decrease in short interest suggests that fewer investors are betting against Biomarin, which could indicate a more positive outlook on the stock. This is further supported by the fact that its short interest is below the peer average, potentially signaling a bullish sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100